Search Results - "Burge, Russel"

Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom.

Authors: Pierce, Evangeline J. Burge, Russel T. Hirst, Alex J. et al.

Source: Dermatology & Therapy. May2024, Vol. 14 Issue 5, p1103-1114. 12p.

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.

Authors: Gottlieb, Alice B. Burge, Russel Malatestinic, William N. et al.

Source: Dermatology & Therapy. Aug2023, Vol. 13 Issue 8, p1831-1846. 16p.

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.

Authors: Blauvelt, Andrew Burge, Russel Gallo, Gaia et al.

Source: Dermatology & Therapy. Mar2022, Vol. 12 Issue 3, p701-714. 14p.

Validation of the real-world application of the Hidradenitis Suppurativa Quality of Life (HiSQOL) score to adults with hidradenitis suppurativa.

Authors: Garg, Amit Burge, Russel Cohee, Andrea et al.

Source: British Journal of Dermatology. Feb2025, Vol. 192, p261-268. 8p.

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Authors: Langley, Richard G. B. Reich, Kristian Strand, Vibeke et al.

Source: Quality of Life Research. Feb2020, Vol. 29 Issue 2, p369-380. 12p. 6 Charts, 2 Graphs.

Subjects: Psoriasis, Quality of life

Posthospital Discharge Medical Care Costs and Family Burden Associated with Osteoporotic Fracture Patients in China from 2011 to 2013.

Authors: Xie, Zhao Burge, Russel Yang, Yicheng et al.

Source: Journal of Osteoporosis. 6/28/2015, Vol. 2015, p1-6. 6p.

Psychometric properties of the osteoporosis patient assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study.

Authors: Wei Shen Burge, Russel Naegeli, April N. et al.

Source: BMC Musculoskeletal Disorders. 2014, Vol. 15 Issue 1, p1-20. 20p. 1 Diagram, 7 Charts.

Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study.

Authors: Burge, Russel Wei Shen Naegeli, April N. et al.

Source: Health & Quality of Life Outcomes. 2013, Vol. 11 Issue 1, p1-22. 22p.

Methodology for Estimating Current and Future Burden of Osteoporosis in State Populations: Application to Florida in 2000 through 2025.

Authors: Burge, Russel T. King, Alison B. Balda, Eric et al.

Source: Value in Health. Sep2003, Vol. 6 Issue 5, p574. 10p.

Inpatient Hospital and Post-Acute Care for Vertebral Fractures in Women.

Authors: Burge, Russel Puleo, Elaine Gehlbach, Stephen et al.

Source: Value in Health. Jul2002, Vol. 5 Issue 4, p301-311. 11p.

Genital Psoriasis: An Updated Review of Diagnosis and Management for Healthcare Providers.

Authors: Guenther, Lyn C. Cather, Jennifer C. Gooderham, Melinda J. et al.

Source: Dermatologic Therapy. 7/11/2026, Vol. 2026, p1-21. 21p.

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.

Authors: Blauvelt, Andrew Shi, Nianwen Somani, Najwa et al.

Source: Clinical Drug Investigation. Mar2023, Vol. 43 Issue 3, p185-196.

Diffusion of Medicare's RBRVS and related physician payment policies.

Authors: McCormack, Lauren A. Burge, Russel T.

Source: Health Care Financing Review. Winter94, Vol. 16 Issue 2, p159. 15p. 4 Charts, 5 Graphs.

Allocating practice expense under the Medicare fee schedule.

Authors: Pope, Gregory C. Burge, Russel T.

Source: Health Care Financing Review. Spring93, Vol. 14 Issue 3, p139. 24p. 3 Charts, 2 Graphs.

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Authors: Blauvelt, Andrew Kircik, Leon Schlesinger, Todd et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-9. 9p.

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.

Authors: Yu, Chen Wang, Gang Burge, Russel T. et al.

Source: Dermatology & Therapy. Jan2023, Vol. 13 Issue 1, p187-206. 20p.

Real-world clinical and economic outcomes for daily teriparatide patients in Japan.

Authors: Burge, Russel Sato, Masayo Sugihara, Tomoko

Source: Journal of Bone & Mineral Metabolism. Nov2016, Vol. 34 Issue 6, p692-702. 11p.

Disease response and patient-reported outcomes among initiators of ixekizumab.

Authors: Shahriari, Mona Harrison, Ryan W. Burge, Russel et al.

Source: Journal of Dermatological Treatment. May2022, Vol. 33 Issue 3, p1538-1546. 9p.

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.

Authors: Blauvelt, Andrew Shi, Nianwen Burge, Russel et al.

Source: Dermatology & Therapy. Dec2021, Vol. 11 Issue 6, p2133-2145. 13p.

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.

Authors: Hawkes, Jason E. See, Kyoungah Burge, Russel et al.

Source: Dermatology & Therapy. Aug2021, Vol. 11 Issue 4, p1107-1118. 12p.